Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is a single-institution, open-label, non-randomized phase IB/II trial of celecoxib
administered concurrently with carboplatin, paclitaxel, and radiation therapy in patients
with locally advanced or recurrent squamous cell carcinoma of the head and neck.